Skip to main content

Cefepime Disease Interactions

There are 5 disease interactions with cefepime.

Major

Antibiotics (applies to cefepime) colitis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Colitis/Enteritis (Noninfectious)

Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.

References

  1. "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories (2002):
  2. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome (2002):
  3. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
  4. "Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn (2002):
  5. "Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
  6. "Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
  7. "Product Information. Amoxil (amoxicillin)." SmithKline Beecham (2001):
  8. "Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals (2001):
  9. "Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis (2001):
  10. "Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn (2001):
  11. "Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc (2003):
  12. "Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals (2004):
  13. "Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical (2007):
  14. "Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc (2009):
  15. "Product Information. Vibativ (telavancin)." Theravance Inc (2009):
  16. "Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals (2010):
  17. "Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc (2022):
  18. "Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc. (2014):
  19. "Product Information. Orbactiv (oritavancin)." The Medicines Company (2014):
  20. "Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions (2017):
  21. "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc. (2017):
  22. "Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC (2022):
  23. "Product Information. Zemdri (plazomicin)." Achaogen (2018):
  24. "Product Information. Seysara (sarecycline)." Allergan Inc (2018):
  25. "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc. (2018):
  26. "Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc. (2018):
  27. "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc (2019):
  28. "Product Information. Biaxin (clarithromycin)." AbbVie US LLC (2019):
  29. "Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group (2021):
  30. "Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals (2018):
View all 30 references
Moderate

Beta-lactams (parenteral) (applies to cefepime) renal dysfunction

Moderate Potential Hazard, High plausibility.

Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites. The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function. Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents. Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling. Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.

References

  1. "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories (2002):
  2. "Product Information. Ancef (cefazolin)." SmithKline Beecham (2002):
  3. "Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn (2002):
  4. "Product Information. Monocid (cefonicid)." SmithKline Beecham (2002):
  5. "Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel (2002):
  6. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals (2002):
  7. "Product Information. Mefoxin (cefoxitin)." Merck & Company Inc (2002):
  8. "Product Information. Fortaz (ceftazidime)." Glaxo Wellcome (2002):
  9. "Product Information. Tazicef (ceftazidime)." SmithKline Beecham (2002):
  10. "Product Information. Cefizox (ceftizoxime)." Fujisawa (2002):
  11. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome (2002):
  12. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
  13. "Product Information. Keflin (cephalothin)." Lilly, Eli and Company (2002):
  14. "Product Information. Cefadyl (cephapirin)." Apothecon Inc (2002):
  15. "Product Information. Staphcillin (methicillin)." Apothecon Inc (2002):
  16. "Product Information. Pfizerpen (penicillin)." Roerig Division (2001):
  17. "Product Information. Pipracil (piperacillin)." Lederle Laboratories (2001):
  18. "Product Information. Ticar (ticarcillin)." SmithKline Beecham (2001):
  19. "Product Information. Mandol (cefamandole)." Lilly, Eli and Company (2001):
  20. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb (2001):
  21. "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc (2019):
View all 21 references
Moderate

Cephalosporins (applies to cefepime) dialysis

Moderate Potential Hazard, High plausibility. Applicable conditions: hemodialysis

Most cephalosporin antibiotics are removed by hemodialysis. Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis. Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.

References

  1. "Product Information. Ceclor (cefaclor)." Lilly, Eli and Company (2002):
  2. "Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb (2002):
  3. "Product Information. Ancef (cefazolin)." SmithKline Beecham (2002):
  4. "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc (2002):
  5. "Product Information. Monocid (cefonicid)." SmithKline Beecham (2002):
  6. "Product Information. Cefobid (cefoperazone)." Roerig Division (2002):
  7. "Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel (2002):
  8. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals (2002):
  9. "Product Information. Mefoxin (cefoxitin)." Merck & Company Inc (2002):
  10. "Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn (2002):
  11. "Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb (2002):
  12. "Product Information. Tazicef (ceftazidime)." SmithKline Beecham (2002):
  13. "Product Information. Cefizox (ceftizoxime)." Fujisawa (2002):
  14. "Product Information. Rocephin (ceftriaxone)." Roche Laboratories (2002):
  15. "Product Information. Keflex (cephalexin)." Dista Products Company (2002):
  16. "Product Information. Velosef (cephradine)." Apothecon Inc (2002):
  17. "Product Information. Keflin (cephalothin)." Lilly, Eli and Company (2002):
  18. "Product Information. Cefadyl (cephapirin)." Apothecon Inc (2002):
  19. "Product Information. Lorabid (loracarbef)." Lilly, Eli and Company (2002):
  20. "Product Information. Mandol (cefamandole)." Lilly, Eli and Company (2001):
  21. "Product Information. Cedax (ceftibuten)." Schering-Plough (2001):
  22. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb (2001):
  23. "Product Information. Omnicef (cefdinir)." Parke-Davis (2001):
  24. "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc (2001):
View all 24 references
Moderate

Cephalosporins (applies to cefepime) liver disease

Moderate Potential Hazard, Moderate plausibility.

Cases of hepatitis have been reported with the use of certain cephalosporins. Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed. Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.

References

  1. "Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn
  2. "Product Information. Ceclor (cefaclor)." Lilly, Eli and Company (2002):
  3. "Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb (2002):
  4. "Product Information. Ancef (cefazolin)." SmithKline Beecham (2002):
  5. "Product Information. Kefzol (cefazolin)." Lilly, Eli and Company (2002):
  6. "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc (2002):
  7. "Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel (2002):
  8. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals (2002):
  9. "Product Information. Mefoxin (cefoxitin)." Merck & Company Inc (2002):
  10. "Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb (2002):
  11. "Product Information. Fortaz (ceftazidime)." Glaxo Wellcome (2002):
  12. "Product Information. Cefizox (ceftizoxime)." Fujisawa (2002):
  13. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome (2002):
  14. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
  15. "Product Information. Keflex (cephalexin)." Dista Products Company (2002):
  16. "Product Information. Cedax (ceftibuten)." Schering-Plough (2001):
  17. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb (2001):
  18. "Product Information. Omnicef (cefdinir)." Parke-Davis (2001):
  19. "Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals (2001):
  20. "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc (2001):
View all 20 references
Moderate

Cephalosporins (applies to cefepime) seizure disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Seizures

Cephalosporins have been implicated in triggering seizures. Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment. Adjust dosing based on creatinine clearance. Anticonvulsant therapy should be continued in patients with known seizure disorders. If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.

References

  1. "Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn
  2. "Product Information. Ceclor (cefaclor)." Lilly, Eli and Company (2002):
  3. "Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb (2002):
  4. "Product Information. Ancef (cefazolin)." SmithKline Beecham (2002):
  5. "Product Information. Kefzol (cefazolin)." Lilly, Eli and Company (2002):
  6. "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc (2002):
  7. "Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel (2002):
  8. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals (2002):
  9. "Product Information. Mefoxin (cefoxitin)." Merck & Company Inc (2002):
  10. "Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb (2002):
  11. "Product Information. Fortaz (ceftazidime)." Glaxo Wellcome (2002):
  12. "Product Information. Cefizox (ceftizoxime)." Fujisawa (2002):
  13. "Product Information. Keflex (cephalexin)." Dista Products Company (2002):
  14. "Product Information. Cedax (ceftibuten)." Schering-Plough (2001):
  15. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb (2001):
  16. "Product Information. Omnicef (cefdinir)." Parke-Davis (2001):
  17. "Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals (2001):
  18. "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc (2001):
  19. "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc (2019):
View all 19 references

Cefepime drug interactions

There are 35 drug interactions with cefepime.


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.